Layrek Clinical Research | Tulsa, OK

Research site

Location

10505 East 91st Street Suite 202, Tulsa, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

BMS-986278

Lunsekimig

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Active trials

3 of 3 total trials

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in participants with Idiopathic Pulmonary Fibrosis.

Active, not recruiting

Idiopathic Pulmonary Fibrosis

Drug: BMS-986278

Drug: BMS-986278 Placebo

A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary Fibrosis

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986278 in Participants with Progressive Pulmonary Fibrosis.

Active, not recruiting

Progressive Pulmonary Fibrosis

Drug: BMS-986278 Placebo

Drug: BMS-986278

Locations recently updated

Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype (THESEUS)

This is a parallel, Phase 2/Phase 3, 3-arm study to investigate the efficacy, safety, and tolerability of subcutaneous (SC) treatment with lunsekimig...

Enrolling

Chronic Obstructive Pulmonary Disease

Drug: Placebo

Drug: Lunsekimig

Trial sponsors

Clinical trials

Find clinical trials Trials by location

Research sites

Find research sites Learn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy Notice Terms